Piramal Healthcare Presents Positive Results of Pivotal Phase III clinical trial for BST-CarGel

The trial represents the first of its kind in cartilage repair using novel, three-dimensional quantitative MRI techniques that substantially improve comparisons of repair cartilage structure (quantity and quality) through standardised data acquisition and precise and blinded analyses.

• BST-CarGel treatment met both co-primary trial endpoints by achieving statistical significance over microfracture in both the degree of filling of treated lesions and the quality of the new tissue.
• Overall, this trial demonstrated that cartilage repair structural outcomes resulting from BST-CarGel treatment were superior at 12 months to microfracture, the current standard of care, with a similar safety profile.
• This represents a critical finding as cartilage structure (quantity and quality) is believed to translate to longer durability and sustained clinical benefit.

http://www.expresspharmaonline.com/index.php/latest-updates/455-piramal-healthcare-presents-positive-results-of-pivotal-phase-iii-clinical-trial-for-bst-cargel